Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Metadata listed "KORU Medical Systems, Inc." but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2009
Business Overview: The Company researches, develops, and markets medical devices, primarily the Freedom60 Syringe Infusion System for home care and the RES-Q-VAC Emergency Airway Suction System. The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2009 |
Six Months Ended Aug 31, 2009 |
|---|---|---|
| Net Sales | $947,056 | $1,760,185 |
| Net Income | $110,611 | $174,664 |
| Net Income Available to Common | $106,611 | $170,664 |
| Gross Margin | 67.8% | 64.9% |
| Operating Profit | $193,249 | $292,071 |
| Cash from Operations | N/A | $26,953 |
| Cash and Equivalents (End of Period) | $497,604 | |
| Total Debt (Current + Long-term) | $745,899 | |
| Working Capital | $1,535,407 |
Note: Gross Margin calculated as (Net Sales - Cost of Goods Sold) / Net Sales.
Material Changes vs. Prior Period
- Revenue: Net sales increased 1.1% for the three months ended August 31, 2009, compared to the same period in 2008. For the six-month period, sales increased 7.6% to $1.76 million.
- Profitability: Net income decreased significantly to $110,611 for the quarter (down from $279,529 in 2008) and to $174,664 for the six months (down from $344,167 in 2008).
- Expenses: Selling, General, and Administrative (SG&A) expenses increased 46% quarter-over-year and 33% year-over-year (six months), driven by increased staffing for new products, higher auditing fees for ISO certification, and legal fees.
- Product Mix: Sales of the Freedom60 system increased 13% due to growth in immune globulin and antibiotic applications. Conversely, RES-Q-VAC sales decreased 12% attributed to a downturn in the emergency market economy.
- Interest Expense: Decreased 35% for the quarter due to the repayment of certain notes outstanding in the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current capital and increased cash flow will meet financial needs for the next twelve months. Approximately $55,000 remains in a government grant (Trade Adjustment Assistance Program) to assist with marketing and regulatory affairs.
- Market Drivers: The Company anticipates continued growth in the subcutaneous immune globulin market for the Freedom60. They are also pursuing Medicare reimbursement coding (HCPCS E0779) to improve provider reimbursement rates.
- Risks:
- Competition: Low-cost Chinese competitors (e.g., Ambu Res Cue Pump) pose a threat to the RES-Q-VAC line.
- Regulatory: Uncertainty regarding continued Medicare reimbursement and FDA regulations.
- Contingencies: The Company is contingently liable for approximately $29,000 in rework costs for a customer order, which has been provisioned.
- Related Party Dependence: Significant debt is owed to the President and a Director, totaling over $675,000 in long-term notes.
Investor Verification Checklist
- Debt Structure: Verify the terms and repayment schedule of the $672,663 loan from a Director and the $100,000 demand loan from the President.
- Grant Utilization: Confirm the status and remaining balance of the $150,000 Trade Adjustment Assistance grant.
- Revenue Concentration: Assess the reliance on the Freedom60 product line versus the declining RES-Q-VAC line.
- Related Party Transactions: Review the issuance of 755,000 shares to a Director to reduce debt and the ongoing aircraft lease with a President-controlled entity.
- Contingent Liability: Monitor the $29,000 provision for rework costs to ensure it does not escalate.